Cargando…
Efficacy of a novel topical combination of esafoxolaner, eprinomectin and praziquantel against fleas in cats, under field conditions
Esafoxolaner is a purified afoxolaner enantiomer with insecticidal and acaricidal properties. It is combined with eprinomectin and praziquantel, nematodicidal and cestodicidal compounds, in a novel topical endectoparasiticide formulation for cats. This novel formulation was tested in four field stud...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
EDP Sciences
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019569/ https://www.ncbi.nlm.nih.gov/pubmed/33812454 http://dx.doi.org/10.1051/parasite/2021018 |
_version_ | 1783674399211126784 |
---|---|
author | Tielemans, Eric Otsuki, Tomoko Cheesman, Tara Selmes, Fiona Pfefferkorn, Anthony Prullage, Joe |
author_facet | Tielemans, Eric Otsuki, Tomoko Cheesman, Tara Selmes, Fiona Pfefferkorn, Anthony Prullage, Joe |
author_sort | Tielemans, Eric |
collection | PubMed |
description | Esafoxolaner is a purified afoxolaner enantiomer with insecticidal and acaricidal properties. It is combined with eprinomectin and praziquantel, nematodicidal and cestodicidal compounds, in a novel topical endectoparasiticide formulation for cats. This novel formulation was tested in four field studies, in the United States, Europe, Japan and Australia. In all studies, naturally flea-infested domestic cats were treated with the novel formulation at the label dose and conditions of use. The main objective, identical in the four studies, was to assess efficacy on fleas, based on comparison of mean number of fleas found on infested cats before and one month after treatment. Tolerance to the product was also evaluated in the four studies. Otherwise, the studies had some differences in their design and secondary objectives, for example testing for a reduction in flea infestation-related cutaneous signs, testing of one treatment or of three monthly treatments, and use of a positive control group. In the four studies, a total of 307 cats were treated with the novel formulation. The reduction of fleas one month after treatment was 97.7%, 98.8%, 100% and 99.7% in the United States, Europe, Japan and Australia, respectively. There were no significant health abnormalities attributed to treatment in any of the studies. |
format | Online Article Text |
id | pubmed-8019569 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | EDP Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-80195692021-04-05 Efficacy of a novel topical combination of esafoxolaner, eprinomectin and praziquantel against fleas in cats, under field conditions Tielemans, Eric Otsuki, Tomoko Cheesman, Tara Selmes, Fiona Pfefferkorn, Anthony Prullage, Joe Parasite Research Article Esafoxolaner is a purified afoxolaner enantiomer with insecticidal and acaricidal properties. It is combined with eprinomectin and praziquantel, nematodicidal and cestodicidal compounds, in a novel topical endectoparasiticide formulation for cats. This novel formulation was tested in four field studies, in the United States, Europe, Japan and Australia. In all studies, naturally flea-infested domestic cats were treated with the novel formulation at the label dose and conditions of use. The main objective, identical in the four studies, was to assess efficacy on fleas, based on comparison of mean number of fleas found on infested cats before and one month after treatment. Tolerance to the product was also evaluated in the four studies. Otherwise, the studies had some differences in their design and secondary objectives, for example testing for a reduction in flea infestation-related cutaneous signs, testing of one treatment or of three monthly treatments, and use of a positive control group. In the four studies, a total of 307 cats were treated with the novel formulation. The reduction of fleas one month after treatment was 97.7%, 98.8%, 100% and 99.7% in the United States, Europe, Japan and Australia, respectively. There were no significant health abnormalities attributed to treatment in any of the studies. EDP Sciences 2021-04-02 /pmc/articles/PMC8019569/ /pubmed/33812454 http://dx.doi.org/10.1051/parasite/2021018 Text en © E. Tielemans et al., published by EDP Sciences, 2021 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Tielemans, Eric Otsuki, Tomoko Cheesman, Tara Selmes, Fiona Pfefferkorn, Anthony Prullage, Joe Efficacy of a novel topical combination of esafoxolaner, eprinomectin and praziquantel against fleas in cats, under field conditions |
title | Efficacy of a novel topical combination of esafoxolaner, eprinomectin and praziquantel against fleas in cats, under field conditions |
title_full | Efficacy of a novel topical combination of esafoxolaner, eprinomectin and praziquantel against fleas in cats, under field conditions |
title_fullStr | Efficacy of a novel topical combination of esafoxolaner, eprinomectin and praziquantel against fleas in cats, under field conditions |
title_full_unstemmed | Efficacy of a novel topical combination of esafoxolaner, eprinomectin and praziquantel against fleas in cats, under field conditions |
title_short | Efficacy of a novel topical combination of esafoxolaner, eprinomectin and praziquantel against fleas in cats, under field conditions |
title_sort | efficacy of a novel topical combination of esafoxolaner, eprinomectin and praziquantel against fleas in cats, under field conditions |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019569/ https://www.ncbi.nlm.nih.gov/pubmed/33812454 http://dx.doi.org/10.1051/parasite/2021018 |
work_keys_str_mv | AT tielemanseric efficacyofanoveltopicalcombinationofesafoxolanereprinomectinandpraziquantelagainstfleasincatsunderfieldconditions AT otsukitomoko efficacyofanoveltopicalcombinationofesafoxolanereprinomectinandpraziquantelagainstfleasincatsunderfieldconditions AT cheesmantara efficacyofanoveltopicalcombinationofesafoxolanereprinomectinandpraziquantelagainstfleasincatsunderfieldconditions AT selmesfiona efficacyofanoveltopicalcombinationofesafoxolanereprinomectinandpraziquantelagainstfleasincatsunderfieldconditions AT pfefferkornanthony efficacyofanoveltopicalcombinationofesafoxolanereprinomectinandpraziquantelagainstfleasincatsunderfieldconditions AT prullagejoe efficacyofanoveltopicalcombinationofesafoxolanereprinomectinandpraziquantelagainstfleasincatsunderfieldconditions |